Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Acacia Research | ACTG | Oct 17, 2024 | 4.77 | +2.36 |
Academy Sports and Outdoors | ASO | Oct 17, 2024 | 55.38 | -0.66 |
Acadia Healthcare | ACHC | Oct 17, 2024 | 59.32 | +3.36 |
Acadia Pharmaceuticals | ACAD | Oct 17, 2024 | 15.17 | +0.86 |
Acadia Realty Trust | AKR | Oct 17, 2024 | 24.45 | -0.81 |
Acasti Pharma, Inc. | ACST | Oct 17, 2024 | 3.28 | -2.04 |
Accel Entertainment | ACEL | Oct 17, 2024 | 11.47 | -0.86 |
Accelerate Diagnostics | AXDX | Oct 17, 2024 | 1.75 | -7.89 |
Accenture A | ACN | Oct 17, 2024 | 375.15 | +0.78 |
Acco Brands | ACCO | Oct 17, 2024 | 5.30 | +1.92 |
Accolade | ACCD | Oct 17, 2024 | 3.58 | -4.53 |
Accuray | ARAY | Oct 17, 2024 | 1.83 | -3.68 |
Acelyrin | SLRN | Oct 17, 2024 | 6.48 | +6.58 |
Achieve Life Sciences | ACHV | Oct 17, 2024 | 5.05 | +1.00 |
Achilles Therapeutics ADR | ACHL | Oct 17, 2024 | 0.99 | 0.00 |
ACI Worldwide | ACIW | Oct 17, 2024 | 51.94 | -1.76 |
Aclarion | ACON | Oct 17, 2024 | 0.17 | +0.18 |
Aclaris Therapeutics | ACRS | Oct 17, 2024 | 1.17 | +0.86 |
ACM Research A | ACMR | Oct 17, 2024 | 19.00 | -2.34 |
Acme United | ACU | Oct 17, 2024 | 43.78 | -1.51 |
ACNB | ACNB | Oct 17, 2024 | 44.16 | +1.31 |
ACRES Commercial Realty | ACR | Oct 17, 2024 | 15.34 | +0.85 |
ACRES Commercial Realty C Pref | ACR-C | Oct 17, 2024 | 24.82 | +0.28 |
ACRES Commercial Realty D Pref | ACR-D | Oct 17, 2024 | 23.25 | +0.67 |
Acri Capital Acquisition Unit | ACACU | Oct 17, 2024 | 12.94 | 0.00 |
Acrivon Therapeutics | ACRV | Oct 17, 2024 | 7.87 | +1.55 |
Actelis Networks | ASNS | Oct 17, 2024 | 1.40 | +1.45 |
Actinium Pharmaceuticals | ATNM | Oct 17, 2024 | 1.72 | +2.38 |
Active Bear ETF | HDGE | Oct 17, 2024 | 18.06 | -0.22 |
Active U.S. Real Estate Powershares | PSR | Oct 17, 2024 | 98.10 | -0.68 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.